Mariko Inoue

Mariko Inoue

Auto-generated profile, based on publicly available information

Mariko Inoue

Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TKToshihiko Komai
Toshihiko Komai
MIMariko Inoue
Mariko Inoue
TOTomohisa Okamura
Tomohisa Okamura
KMKaoru Morita
Kaoru Morita
YIYukiko Iwasaki
Yukiko Iwasaki
KFKeishi Fujio
Keishi Fujio
Inhibitory cytokines, such as transforming growth factor-β (TGF-β) and interleukin-10 (IL-10), are humoral factors involved in the suppressive function of regulatory T cells and play critical roles in maintaining immune homeostasis. However, TGF-β and IL-10 also have pleiotropic effects and induce humoral immune responses depending on conditions, and thus their therapeutic application to autoimmune diseases remains limited. Here, we show that a combination of TGF-β and IL-10, but not single cytokine, is required to suppress B cell activation induced by toll-like receptor (TLR) stimulation. In in vivo analyses, the simultaneous presence of TGF-β and IL-10 effectively suppressed TLR-mediated antigen-specific immune responses and ameliorated pathologies in imiquimod (TLR7 agonist)-induced lupus model and lupus-prone MRL/lpr mice. Intriguingly, TGF-β and IL-10 synergistically modulated transcriptional programs and suppressed cellular energetics of both glycolysis and oxidative phosphorylation via inhibition of the mammalian target of rapamycin complex 1 (mTORC1)/S6 kinase 1 (S6K1) pathway in TLR-stimulated B cells. On the other hand, enhancement of mTOR signaling and mitochondrial biosynthesis in TLR-stimulated B cells counteracted the synergistic inhibitory effects. The inhibitory cytokine synergy of TGF-β and IL-10 via suppression of energy metabolism was also observed in human TLR-stimulated B cells. There is increasing evidence supporting the importance of adequate metabolic signals in various immune cells to exert their immune function. In this study, we have shown that a previously unrecognized synergy of inhibitory cytokines regulates systemic humoral immune responses via modulating immunometabolism in B cells. Our findings indicate that inhibition of B cell metabolism mediated by two synergistic cytokines contributes to the induction of immune tolerance and could be a new therapeutic strategy for autoimmune diseases such as systemic lupus erythematosus.

19 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
TOTomohisa Okamura
Tomohisa Okamura
SSShuji Sumitomo
Shuji Sumitomo
KMKaoru Morita
Kaoru Morita
YIYukiko Iwasaki
Yukiko Iwasaki
MIMariko Inoue
Mariko Inoue
KYKazuhiko Yamamoto
Kazuhiko Yamamoto
Autoantibodies induce various autoimmune diseases, including systemic lupus erythematosus (SLE). We previously described that CD4+CD25−LAG3+ regulatory T cells (LAG3+ Treg) are regulated by Egr2, a zinc-finger transcription factor required for the induction of T-cell anergy. We herein demonstrate that LAG3+ Treg produce high amounts of TGF-β3 in an Egr2- and Fas-dependent manner. LAG3+ Treg require TGF-β3 to suppress B-cell responses in a murine model of lupus. Moreover, TGF-β3- and LAG3+ Treg-mediated suppression requires PD-1 expression on B cells. We also show that TGF-β3-expressing human LAG3+ Treg suppress antibody production and that SLE patients exhibit decreased frequencies of LAG3+ Treg. These results clarify the mechanism of B-cell regulation and suggest therapeutic strategies.

1 September 2016 in Autoimmunity Reviews
Verified
Journal Article
Closed access
KFKeishi Fujio
Keishi Fujio
TKToshihiko Komai
Toshihiko Komai
MIMariko Inoue
Mariko Inoue
KMKaoru Morita
Kaoru Morita
TOTomohisa Okamura
Tomohisa Okamura
KYKauzhiko Yamamoto
Kauzhiko Yamamoto

30 November 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KMKaoru Morita
Kaoru Morita
TOTomohisa Okamura
Tomohisa Okamura
MIMariko Inoue
Mariko Inoue
TKToshihiko Komai
Toshihiko Komai
STShuzo Teruya
Shuzo Teruya
KFKeishi Fujio
Keishi Fujio
Significance: Transcription factors early growth response gene 2 (Egr2) and Egr3 have long been regarded as negative regulators of T-cell activation.Egr2is also known as a susceptibility gene for systemic lupus erythematosus characterized by dysregulated humoral immune responses to autoantigens. Previously, we reported that Egr2-expressing CD4+CD25-LAG3+regulatory T cells regulate lupus pathogenesis via production of TGF-β3. However, the role of Egr2 and Egr3 in the regulation of humoral immunity is unclear. Here we report that Egr2 and Egr3 regulate germinal center reactions by promoting TGF-β3 production from regulatory T cells. Egr2 and Egr3 induce the expression of latent TGF-β binding protein 3 (Ltbp3), which is required for TGF-β3 secretion. These findings suggest that Egr2 and Egr3 in T cells may be potential novel therapeutic targets for autoantibody-mediated autoimmune diseases.

4 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YTYumi Tsuchida
Yumi Tsuchida
SSShuji Sumitomo
Shuji Sumitomo
KIKazuyoshi Ishigaki
Kazuyoshi Ishigaki
ASAkari Suzuki
Akari Suzuki
YKYuta Kochi
Yuta Kochi
KFKeishi Fujio
Keishi Fujio
TGF-β is a pleotropic cytokine involved in various biological processes. Of the three isoforms of TGF-β, TGF-β1 has long been recognized as an important inhibitory cytokine in the immune system and has been reported to inhibit B cell function in both mice and humans. Recently, it has been suggested that TGF-β3 may play an important role in the regulation of immune system in mice. Murine CD4+CD25-LAG3+ regulatory T cells suppress B cell function through the production of TGF-β3, and it has been reported that TGF-β3 is therapeutic in a mouse model of systemic lupus erythematosus. The effect of TGF-β3 on human B cells has not been reported, and we herein examined the effect of TGF-β3 on human B cells. TGF-β3 suppressed B cell survival, proliferation, differentiation into plasmablasts, and antibody secretion. Although the suppression of human B cells by TGF-β1 has long been recognized, the precise mechanism for the suppression of B cell function by TGF-β1 remains elusive; therefore, we examined the effect of TGF-β1 and β3 on pathways important in B cell activation and differentiation. TGF-β1 and TGF-β3 inhibited some of the key molecules of the cell cycle, as well as transcription factors important in B cell differentiation into antibody secreting cells such as IRF4, Blimp-1, and XBP1. TGF-β1 and β3 also inhibited B cell receptor signaling. Our results suggest that TGF-β3 modifying therapy might be therapeutic in autoimmune diseases with B cell dysregulation in humans.

7 February 2014 in Modern Rheumatology
Verified
Journal Article
Closed access
HTHaruka Tsuchiya
Haruka Tsuchiya
HTHirotaka Tsuno
Hirotaka Tsuno
MIMariko Inoue
Mariko Inoue
YTYuko Takahashi
Yuko Takahashi
HYHiroyuki Yamashita
Hiroyuki Yamashita
AMAkio Mimori
Akio Mimori